Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 1042.95, up by 5.60 points or 0.54% from its previous closing of Rs. 1037.35 on the BSE.

The scrip opened at Rs. 1024.00 and has touched a high and low of Rs. 1048.00 and Rs. 1009.00 respectively. So far 90062 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1048.00 on 09-Mar-2015 and a 52 week low of Rs. 552.50 on 14-Mar-2014.

Last one week high and low of the scrip stood at Rs. 1048.00 and Rs. 870.00 respectively. The current market cap of the company is Rs. 214945.39 crore.

The promoters holding in the company stood at 63.65% while Institutions and Non-Institutions held 26.55% and 9.80% respectively.

Sun Pharmaceutical Industries’ US-based unit Sun Pharma Global Fze has voluntarily recalled 5,322 bottles of Ketorolac Tromethamine ophthalmic solution in the US market for failing to meet specifications.

The ophthalmic solution falls under non-steroidal anti-inflammatory drug (NSAID) category and is indicated for relief from pain and inflammation in the eyes. The drug was manufactured by Mumbai-based Sun Pharmaceutical Industries at its Halol facility in Gujarat and distributed by Caraco Pharmaceutical Laboratories in the US market. The recall was initiated by the company on January 21 this year.

Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.